Background. Considerable uncertainty remains as to whether early initiation of antiretroviral therapy (ART) in children with vertically acquired human immunodeficiency virus (HIV) infection increases the benefit in terms of immunological response. Methods. The association between immunological outcome and early initiation of and/or more-potent ART was investigated, using age-standardized z scores for CD4 cell counts (hereafter, "CD4 z scores"), in 131 HIV-infected children enrolled in the European Collaborative Study, a birth cohort study. Results. Median age at initiation of the most-potent ART was 4 years (range, 0.1-15.5 years). Initiation of treatment after 5 months of age resulted in nonsignificantly lower CD4 z scores 6 months after initiation. Time to a 20% increase in CD4 z score was associated with age at initiation of the most-potent ART (adjusted hazard ratios [AHRs], 0.37 [P<.01] and 0.43 [P = .05] for 5 months-5 years of age and >5 years of age, respectively, compared with <5 months of age), ethnicity (AHR, 0.48 [P = .01], for black vs. white), and highly active ART (HAART) with or without prior ART (AHRs, 3.16 [P<.01] and 3.95 [P<.001], vs. mono or dual ART, respectively). The risk of subsequent deterioration of CD4 z score was similar for children who initiated ART in different age groups (χ2 = 0.824; P = .82). Conclusions. We confirm the effectiveness of HAART with respect to the recovery of CD4 cell count and suggest a benefit of initiating ART before the age of 5 months. Age at initiation of the most-potent ART was not associated with the likelihood of sustaining the recovery of CD4 cell count.

CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: Is it associated with age at initiation? / M.-. Newell, C. Giaquinto, O. Rampon, V. Giacomet, A. De Rossi, I. Grosch-Worner, J. Mok, I. Bates, I. de Jose, F. Hawkins, M.C. Garcia-Rodriguez, C. Ladron de Guevara, J. Ma Pena, J. Gonzalez Garcia, J.R. Arribas Lopez, F. Asensi-Botet, M.C. Otero, D. Perez-Tamarit, A. Orti, M.J. San Miguel, H. Scherpbier, M. Kreyenbroek, K. Boer, A.B. Bohlin, E. Belfrage, L. Naver, J. Levy, M. Hainaut, A. Peltier, T. Goetghebuer, P. Barlow, A. Ferrazin, D. Bassetti, A. de Maria, C. Gotta, A. Mur, M.A. Lopez-Vilchez, A. Paya, R. Carreras, N. H. Valerius. - In: THE JOURNAL OF INFECTIOUS DISEASES. - ISSN 0022-1899. - 193:7(2006), pp. 954-962.

CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: Is it associated with age at initiation?

V. Giacomet;C. Gotta;A. Paya;
2006

Abstract

Background. Considerable uncertainty remains as to whether early initiation of antiretroviral therapy (ART) in children with vertically acquired human immunodeficiency virus (HIV) infection increases the benefit in terms of immunological response. Methods. The association between immunological outcome and early initiation of and/or more-potent ART was investigated, using age-standardized z scores for CD4 cell counts (hereafter, "CD4 z scores"), in 131 HIV-infected children enrolled in the European Collaborative Study, a birth cohort study. Results. Median age at initiation of the most-potent ART was 4 years (range, 0.1-15.5 years). Initiation of treatment after 5 months of age resulted in nonsignificantly lower CD4 z scores 6 months after initiation. Time to a 20% increase in CD4 z score was associated with age at initiation of the most-potent ART (adjusted hazard ratios [AHRs], 0.37 [P<.01] and 0.43 [P = .05] for 5 months-5 years of age and >5 years of age, respectively, compared with <5 months of age), ethnicity (AHR, 0.48 [P = .01], for black vs. white), and highly active ART (HAART) with or without prior ART (AHRs, 3.16 [P<.01] and 3.95 [P<.001], vs. mono or dual ART, respectively). The risk of subsequent deterioration of CD4 z score was similar for children who initiated ART in different age groups (χ2 = 0.824; P = .82). Conclusions. We confirm the effectiveness of HAART with respect to the recovery of CD4 cell count and suggest a benefit of initiating ART before the age of 5 months. Age at initiation of the most-potent ART was not associated with the likelihood of sustaining the recovery of CD4 cell count.
older children; adolescents; mortality; infants
Settore MED/38 - Pediatria Generale e Specialistica
Article (author)
File in questo prodotto:
File Dimensione Formato  
193-7-954.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 405.24 kB
Formato Adobe PDF
405.24 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/728846
Citazioni
  • ???jsp.display-item.citation.pmc??? 31
  • Scopus 58
  • ???jsp.display-item.citation.isi??? 58
social impact